A microenvironment-adaptive GelMA-ODex@RRHD hydrogel for responsive release of HS in promoted chronic diabetic wound repair.

Chronic diabetic wounds present significant treatment challenges due to their complex microenvironment, often leading to suboptimal healing outcomes. Hydrogen sulfide (HS), a crucial gaseous signaling molecule, has shown great potential in modulating inflammation, oxidative stress and extracellular matrix remodeling, which are essential for effective wound healing. However, conventional HS delivery systems lack the adaptability required to meet the dynamic demands of different healing stages, thereby limiting their therapeutic efficacy.

Efficacy of Revisional Endoscopic Sleeve Gastroplasty After Laparoscopic Sleeve Gastrectomy.

Background: Recurrent weight gain after laparoscopic sleeve gastrectomy (LSG) is common. Revisional endoscopic sleeve gastroplasty (r-ESG) has been shown to be a promising endoscopic bariatric therapy (EBT) to treat weight recurrence after LSG. However, to date, weight loss outcomes beyond 1-year follow-up are unknown.

A modified suture technique using polydioxanone (PDS II) for capsule closure in total knee arthroplasty: a prospective randomized study compared with traditional suture technique.

Purpose: To describe and evaluate the modified suture technique using PDS II for capsule closure in Total knee arthroplasty.

Methods: One hundred-five patients with end-stage osteoarthritis of the knee received Total knee arthroplasty (TKA) in our department. The arthrotomy wounds were closed randomly utilizing either modified suture (the MS group, 53 patients) or traditional suture (the TS group, 52 patients) techniques.

Defining ortholog-specific UHRF1 inhibition by STELLA for cancer therapy.

UHRF1 maintains DNA methylation by recruiting DNA methyltransferases to chromatin. In mouse, these dynamics are potently antagonized by a natural UHRF1 inhibitory protein STELLA, while the comparable effects of its human ortholog are insufficiently characterized, especially in cancer cells. Herein, we demonstrate that human STELLA (hSTELLA) is inadequate, while mouse STELLA (mSTELLA) is fully proficient in inhibiting the abnormal DNA methylation and oncogenic functions of UHRF1 in human cancer cells.